Stock comparison
Artivion
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AORT
Artivion
Market cap
$1.09B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AORT | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 35D | 72B | LLY |
| Benjamin Graham | 63D | 86A | LLY |
| Philip Fisher | 48D | 86A | LLY |
| Peter Lynch | 32F | 74B | LLY |
| Joel Greenblatt | 41D | 78C | LLY |
| Charlie Munger | 43D | 85A | LLY |
| Terry Smith | 36D | 77C | LLY |
Side-by-side metrics
| Metric | AORT | LLY |
|---|---|---|
| Market cap | $1.09B | $1T |
| P/E (TTM) | 93.6x | 36.6x |
| EV/EBIT | 48.9x | 34.1x |
| ROIC (TTM) | 3.0% | 32.06% |
| Gross margin | 62.94% | 83.51% |
| Net margin | 2.55% | 34.98% |
| Revenue CAGR 5y | 10.24% | 23.17% |
| EPS CAGR 5y | - | 40.81% |
| Debt / Equity | 0.6x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AORT leads on
- Debt / Equity0.6xvs 1.4x+59%
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $1.09B+100%
- Net margin34.98%vs 2.55%+93%
- ROIC (TTM)32.06%vs 3.0%+91%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.